Austin, Texas, United States, October 7th, 2026, NewsDirect
- New agreement moves innovative Lucid-MS treatment from planning into execution.
- Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system.
- Thermo Fisher's clinical research business is a leading global contract research organization, with impressive expertise in central nervous system and MS studies.
Most multiple sclerosis ("MS") drugs work by quieting the immune system. A new partnership shines the spotlight on a different approach -- protecting the nerve's own insulation -- and sets up that treatment for a rigorous clinical test. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific. The contract covers implementation of the phase 2 trial of Lucid-MS, Quantum's lead drug candidate for MS.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN Austin, Texas www.IBN.ai 512.354.7000 Office Editor@IBN.ai